Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

A genomic analysis of patients with chronic lymphocytic leukemia treated with fixed duration therapy in a first-line setting in alberta, Canada

View Full Paper
Ask AI
Bookmark
Share

Authors

SGSydney GeorgeMSMariet Mathew Stephen

Discussion

Loading...

Member takes

Overview

Observational study reveals genetic testing gaps and treatment patterns in chronic lymphocytic leukemia patients receiving targeted therapies.

Key Points

  • This study aims to characterize the genomic and clinical profiles of patients with chronic lymphocytic leukemia receiving first-line fixed duration therapy.
  • Conducted a retrospective observational study using Alberta, Canada health data.
  • Identified 589 adult patients diagnosed with chronic lymphocytic leukemia initiating first-line fixed duration therapy.
  • Performed chart extraction for genetic testing rates and treatment patterns among a selected cohort.
  • 85% of patients received a first-line chemoimmunotherapy regimen, while 15% received a targeted fixed-durations regimen.
  • Genomic testing rates were 48% for IGHV and 60% for del(17p).
  • Among targeted therapy patients, genomic testing rates were 93.5%-100%, indicating higher testing adherence.

Cite This Study

George et al. (2025) studied this question.

synapsesocial.com/papers/69362f5d4fa91c937236dc37https://doi.org/10.1182/blood-2025-8013
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world selection of fixed-duration versus continuous therapies for treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma2025
  2. 2Real-world chronic lymphocytic leukemia (CLL)–specific biomarker testing patterns and frontline treatment patterns in patients with CLL/small lymphocytic lymphoma (SLL)2025
  3. 3Impact of testing for genetic markers on treatment selection and clinical outcomes among patients with chronic lymphocytic leukemia2025
  4. 4An international view on the current approaches to frontline chronic lymphocytic leukemia therapy2025
  5. 5Contemporary Fixed-Duration Treatment Options in the First-Line Setting of Chronic Lymphocytic Leukemia: Perspectives from a Publicly Funded Healthcare System2025 · 3 citations